Medtronic is on the defensive again with InFuse. Will the Yale review redeem it?
Medtronic (NYSE:MDT) is once again on the defensive regarding its controversial bone graft product InFuse that some claim is unsafe. The Senate Finance Committee, which began to investigate the off-label use of the product last year, has released a devastating report charging, among other things, that the Minnesota medical device maker improperly promoted the product […]